Drug intelligence / Profile preview

J9003

Development stage: Unknown
Lead developer: HBM Holdings
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

J9003 is a monoclonal antibody currently in Phase 1 clinical development for the treatment of inflammatory bowel disease (IBD). Developed by Harbour BioMed (HBMK), the specific biological target of this therapeutic candidate remains undisclosed. The drug is designed to address the underlying inflammatory processes associated with IBD, which includes conditions such as Crohn's disease and ulcerative colitis. J9003 represents part of Harbour BioMed's broader effort to leverage its proprietary antibody discovery platforms to create novel treatments for autoimmune and inflammatory diseases.

Beyond the preview

Go deeper on J9003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J9003.

Explore the full profile